Bora CDMO Bora CDMO

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu

    Find the latest Drugs in Development and Pipeline Prospector News of Akums Lifesciences.

    Client Virtual Booth

    AKUMS LIFESCIENCES

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    APIs // Active Pharmaceutical Ingredients

    DEVELOPMENTS

    INSPECTIONS & REGISTRATIONS

    PharmaCompass
    Contact SupplierContact Supplier
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Send me more info on How To Grow My Bussiness Digitally?
    Akums Lifesciences
    india-flag Flag
    Country
    Country
    India
    Address
    Address
    301, Laxmi Tower-II, LSC Block-C, Saraswati Vihar, New Delhi – 110 034
    Telephone
    Telephone
    +91-8755507983
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://akumslifesciences.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/akums-lifesciences-limited/
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Full View ScreenFull Screen View
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Akums Launches Lasmiditan Tablet to Alleviate Symptoms Associated with Migraine

    Details:

    Reyvow-Generic (lasmiditan hemisuccinate) belongs to the “selective serotonin receptor agonists” class of medications and is specifically designed to alleviate the symptoms associated with migraine headaches.


    Lead Product(s): Lasmiditan

    Therapeutic Area: Neurology Product Name: Reyvow-Generic

    Highest Development Status: ApprovedProduct Type: Small molecule

    Partner/Sponsor/Collaborator: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable January 05, 2024

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Akums gets DCGI Approval for Perampanel Oral Suspension

    Details:

    Perampanel oral suspension is first-in-class anti-epileptic agent, With epileptic seizures being mediated by neurotransmitter glutamate, agent is highly selective, noncompetitive AMPA receptor antagonist that reduces neuronal hyperexcitation associated with seizures.


    Lead Product(s): Perampanel

    Therapeutic Area: Neurology Product Name: Fycompa-Generic

    Highest Development Status: ApprovedProduct Type: Small molecule

    Partner/Sponsor/Collaborator: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable June 27, 2023

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    euroapi-m-2024-04-29

    Access Virtual Booth

    Contact Supplier

    Send me more info on How To Grow My Business Digitally?
    Post Enquiry
    POST ENQUIRY

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search